Overview Dividends

(ECL) Ecolab - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2788651006

Water Treatment, Hygiene Products, Infection Prevention, Pest Control

ECL EPS (Earnings per Share)

EPS Growth (3Y CAGR): 19.44%
EPS Trend (3Y Correlation): 81.2%

ECL Revenue

Revenue Growth (3Y CAGR): 4.70%
Revenue Trend (3Y Correlation): 64.3%

Risk via 10d forecast
Volatility	21.6%
Value at Risk 5%th	34.0%

Reward
Sharpe Ratio	0.18
Alpha Jensen	-8.46

Character
Hurst Exponent	0.476
Beta	0.989

Drawdowns 3y
Max DD	17.26%
Mean DD	3.42%

Description: ECL Ecolab September 26, 2025

Ecolab Inc. (NYSE:ECL) delivers water, hygiene, and infection-prevention solutions worldwide through four reportable segments: Global Industrial, Global Institutional & Specialty, Global Healthcare & Life Sciences, and Global Pest Elimination. The company’s product portfolio spans water-treatment chemicals, cleaning and sanitizing agents, and pest-control services, sold via field sales teams, corporate accounts, distributors, and dealers.

In FY 2023 Ecolab generated roughly $13.5 billion in revenue, with an adjusted operating margin of about 14 % and a free-cash-flow conversion rate near 70 %. The Global Industrial segment remains the largest revenue driver, benefiting from rising demand for water-recycling technologies in energy-intensive industries, while the Healthcare & Life Sciences segment is gaining traction as hospitals and pharma firms increase spending on infection-control protocols post-COVID-19.

Key macro-economic levers include global industrial production growth (especially in emerging markets), tightening environmental regulations that spur water-conservation investments, and inflationary pressure on raw-material costs, which can compress margins if not offset by pricing power. Ecolab’s historical ability to pass through cost increases and its focus on recurring service contracts provide a partial hedge against these risks.

For a deeper, data-driven look at Ecolab’s valuation scenarios and sensitivity analyses, the resources available on ValueRay may prove helpful.

ECL Stock Overview

Market Cap in USD	72,545m
Sub-Industry	Specialty Chemicals
IPO / Inception	1988-01-05
Return 12m vs S&P 500	-8.50%
Analyst Rating	3.73 of 5

ECL Dividends

Dividend Yield	0.99%
Yield on Cost 5y	1.32%
Yield CAGR 5y	5.71%
Payout Consistency	96.7%
Payout Ratio	35.8%

ECL Growth Ratios

CAGR	21.25%
CAGR/Max DD Calmar Ratio	1.23
CAGR/Mean DD Pain Ratio	6.20
Current Volume	893.3k
Average Volume	1625.2k

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (1.98b TTM) > 0 and > 6% of Revenue (6% = 953.4m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA -2.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 18.37% (prev 8.99%; Δ 9.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.11 (>3.0%) and CFO 2.63b > Net Income 1.98b (YES >=105%, WARN >=100%)

Net Debt (6.87b) to EBITDA (3.42b) ratio: 2.01 <= 3.0 (WARN <= 3.5)

Current Ratio 1.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (285.4m) change vs 12m ago -0.21% (target <= -2.0% for YES)

Gross Margin 44.32% (prev 43.15%; Δ 1.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 69.09% (prev 70.92%; Δ -1.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 6.84 (EBITDA TTM 3.42b / Interest Expense TTM 282.3m) >= 6 (WARN >= 3)

Altman Z'' 3.88

(A) 0.12 = (Total Current Assets 7.11b - Total Current Liabilities 4.19b) / Total Assets 23.90b

(B) 0.52 = Retained Earnings (Balance) 12.48b / Total Assets 23.90b

(D) 0.77 = Book Value of Equity 10.94b / Total Liabilities 14.14b

Total Rating: 3.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 68.67

1. Piotroski 6.50pt = 1.50

2. FCF Yield 1.96% = 0.98

3. FCF Margin 9.78% = 2.44

4. Debt/Equity 0.91 = 2.10

5. Debt/Ebitda 2.01 = -0.02

6. ROIC - WACC (= 0.79)% = 0.99

7. RoE 21.58% = 1.80

8. Rev. Trend 64.29% = 4.82

9. EPS Trend 81.16% = 4.06

What is the price of ECL shares?

As of November 12, 2025, the stock is trading at USD 262.05 with a total of 893,302 shares traded.
Over the past week, the price has changed by +1.31%, over one month by -3.02%, over three months by -3.96% and over the past year by +5.64%.

Is Ecolab a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Ecolab (NYSE:ECL) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 68.67 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ECL is around 252.20 USD . This means that ECL is currently overvalued and has a potential downside of -3.76%.

Is ECL a buy, sell or hold?

Ecolab has received a consensus analysts rating of 3.73. Therefor, it is recommend to hold ECL.

Strong Buy: 8
Buy: 4
Hold: 13
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the ECL price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	291.8	11.3%
Analysts Target Price	291.8	11.3%
ValueRay Target Price	281.6	7.5%

ECL Fundamental Data Overview November 11, 2025

Market Cap USD = 72.55b (72.55b USD * 1.0 USD.USD)
P/E Trailing = 36.9063
P/E Forward = 32.2581
P/S = 4.5653
P/B = 8.3381
P/EG = 2.9303
Beta = 0.989
Revenue TTM = 15.89b USD
EBIT TTM = 1.93b USD
EBITDA TTM = 3.42b USD
Long Term Debt = 6.95b USD (from longTermDebt, last fiscal year)
Short Term Debt = 176.5m USD (from shortTermDebt, last quarter)
Debt = 8.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.87b USD (from netDebt column, last quarter)
Enterprise Value = 79.42b USD (72.55b + Debt 8.83b - CCE 1.96b)
Interest Coverage Ratio = 6.84 (Ebit TTM 1.93b / Interest Expense TTM 282.3m)
FCF Yield = 1.96% (FCF TTM 1.55b / Enterprise Value 79.42b)
FCF Margin = 9.78% (FCF TTM 1.55b / Revenue TTM 15.89b)
Net Margin = 12.49% (Net Income TTM 1.98b / Revenue TTM 15.89b)
Gross Margin = 44.32% ((Revenue TTM 15.89b - Cost of Revenue TTM 8.85b) / Revenue TTM)
Gross Margin QoQ = 44.79% (prev 44.78%)
Tobins Q-Ratio = 3.32 (Enterprise Value 79.42b / Total Assets 23.90b)
Interest Expense / Debt = 0.63% (Interest Expense 55.3m / Debt 8.83b)
Taxrate = 17.83% (128.0m / 717.7m)
NOPAT = 1.59b (EBIT 1.93b * (1 - 17.83%))
Current Ratio = 1.70 (Total Current Assets 7.11b / Total Current Liabilities 4.19b)
Debt / Equity = 0.91 (Debt 8.83b / totalStockholderEquity, last quarter 9.72b)
Debt / EBITDA = 2.01 (Net Debt 6.87b / EBITDA 3.42b)
Debt / FCF = 4.43 (Net Debt 6.87b / FCF TTM 1.55b)
Total Stockholder Equity = 9.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.30% (Net Income 1.98b / Total Assets 23.90b)
RoE = 21.58% (Net Income TTM 1.98b / Total Stockholder Equity 9.20b)
RoCE = 11.96% (EBIT 1.93b / Capital Employed (Equity 9.20b + L.T.Debt 6.95b))
RoIC = 9.46% (NOPAT 1.59b / Invested Capital 16.78b)
WACC = 8.67% (E(72.55b)/V(81.38b) * Re(9.66%) + D(8.83b)/V(81.38b) * Rd(0.63%) * (1-Tc(0.18)))
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.30%
[DCF Debug] Terminal Value 74.52% ; FCFE base≈1.73b ; Y1≈1.95b ; Y5≈2.61b
Fair Price DCF = 120.5 (DCF Value 34.14b / Shares Outstanding 283.2m; 5y FCF grow 14.34% → 3.0% )
EPS Correlation: 81.16 | EPS CAGR: 19.44% | SUE: 0.0 | # QB: 0
Revenue Correlation: 64.29 | Revenue CAGR: 4.70% | SUE: 2.10 | # QB: 1

Additional Sources for ECL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle